The growing prevalence of PTSD in our society has devastating consequences for afflicted individuals and their loved ones. New treatments using MDMA combined with psychotherapy have shown success in treating this intractable condition. This talk summarizes preliminary qualitative findings from the MAPS Phase II clinical trial on MDMA-assisted therapy for treatment-resistant PTSD. Study participants were interviewed one year after treatment ended, where they were given the chance to express how they integrated the benefits from the treatment back into their personal contexts and life routines. From this information, researchers were able to explore the nuances of participants’ unique experience during and after the study, analyze common improvements and challenges faced by participants after treatment ended, and investigate factors that may contribute to long-term success. Since this is the first qualitative analysis on a clinical trial for MDMA-assisted therapy, the talk also addresses the importance of qualitative research in the field, and suggestions for how to improve upon the research.